Navigation Links
Researchers study new drug and indications for heated chemotherapy treatment

WINSTON-SALEM, N.C. Studies have shown that surgery combined with Intraperitoneal Hyperthermic Chemotherapy (IPHC) can improve survival rates for select patients with peritoneal carcinoma (cancer of the lining of the abdominal cavity) that has spread from colorectal or appendix cancer.

Researchers from Wake Forest University School of Medicine will present findings from two studies on the use of IPHC in treating peritoneal cancer that has spread from these two primary cancer sites at the annual meeting of the Society of Surgical Oncology in Chicago, March 13-16.

John H. Stewart, IV, M.D., assistant professor of surgery, section of surgical oncology, reports March 13 on the results of a study evaluating toxicity when combining surgery and IPHC using oxaliplatin as the chemotherapy agent in patients with peritoneal cancer which originated as colorectal or appendix cancer.

A large body of literature suggests that oxaliplatin is superior to other chemotherapy agents in killing colorectal cancer cells, said Stewart. Further, we have previously demonstrated that the cancer-killing effects of oxaliplatin are increased when the agent is heated during perfusion.

The purpose of the phase I study was to establish the maximum tolerated dose of oxaliplatin used in IPHC treating colorectal and appendix cancers that have spread to the peritoneum.

Fifteen patients were enrolled in the study at two dose levels, 200 mg/m and 250 mg/m. At the maximum tolerated dose of 200 mg/m, only two significant toxicities were encountered. More severe toxicities were observed in patients receiving 250 mg/m.

Researchers concluded that IPHC with 200 mg/m of oxaliplatin is well tolerated and is the maximally tolerated dose for a two-hour chemoperfusion.

Based on the data from this phase I study, we propose to conduct a larger trial with oxaliplatin dose to study its efficacy in improving outcomes in patients with peritoneal carcinoma, said Stewart.

On March 14, Perry Shen, M.D. associate professor, section of surgical oncology, will report findings on the use of IPHC in patients with peritoneal cancer and hepatic metastases (HM), or liver cancer that has metastasized from colorectal cancer. The use of IPHC in patients with this presentation is controversial.

This was a retrospective study of 144 patients undergoing surgery to remove as much of the cancer as possible and IPHC between 1991 and 2007, said Shen. There were 17 patients with HM. Clinical and pathological information was obtained from a prospectively collected database and electronic medical record.

Median overall survival for patients with and without HM was 22.7 months and 15.8 months respectively, which was not a significant difference. Two- and four-year survival rates for the HM patients were 34.0 percent and 11.3 percent. Further analysis demonstrated the presence of malignant fluid in the abdominal cavity to be a significant predictor of decreased survival in patients with HM.

We concluded that patients with peritoneal carcinoma and hepatic metastases undergoing cytoreductive surgery and IPHC for colorectal cancer had no significant difference in overall survival compared to those without HM, said Shen. In select patients with peritoneal carcinoma and hepatic metastases, cytoreductive surgery and IPHC may have some benefit. Malignant ascites, an accumulation of fluid in the peritoneal cavity, predicted a poor outcome.


Contact: Jonnie Rohrer
Wake Forest University Baptist Medical Center

Related medicine news :

1. Researchers use light to detect Alzheimers
2. Penn researchers identify first sex chromosome gene involved in meiosis and male infertility
3. Mayo Researchers Say ECG Standards Should Be Revised for Elderly
4. Mayo researchers say ECG standards should be revised for elderly
5. Researchers confirm link between common cold and ear infection
6. Researchers make case for standardized analysis of cardiac imaging
7. Researchers find cause of severe allergic reaction to cancer drug
8. Researchers develop a method to select eggs with the best chance of leading to successful pregnancy
9. USC researchers find benefit for lymphoma patients in combined PET-CT scanning
10. Researchers ID behavioral risk factors for head and neck cancers
11. Red-light cameras increase crashes, researchers find
Post Your Comments:
(Date:11/26/2015)... Karnataka (PRWEB) , ... November ... ... innovative online platform for mental health and wellness consultation, has collaborated with ... to holistically address their reader’s queries on topics on mental and emotional ...
(Date:11/25/2015)... ... November 25, 2015 , ... As part of a global ... attracts volunteers together who want to combine talents and resources to help create ... the process. The non-profit launched its first major fundraiser on November 6, 2015 ...
(Date:11/25/2015)... Omaha, Neb. (PRWEB) , ... November 25, 2015 ... ... nurse staffing companies, has been recognized once again for its stellar workplace culture ... Places to Work.” , Medical Solutions’ Cincinnati office was named a ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior ... (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, civil societies ... the opening of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article published ... and more widely heralded as a breakthrough for performing hernia repairs. The article explains ... laparoscopic surgery is that it can greatly reduce the pain that a patient might ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 ... of self-monitoring blood glucose devices was valued at $11,171.1 ... with a CAGR of 5.7% during 2015 - 2022. ... population and increasing prevalence of diabetes. In addition, the ... care is also contributing to the growth of the ...
(Date:11/25/2015)... , November 25, 2015 Developmental, commercial, ... role in boosting the profitability of pharmaceutical products, ... commercial, and regulatory/legal strategies all play a ... says GBI Research . --> ... play a key role in boosting the profitability of pharmaceutical products, ...
(Date:11/25/2015)... 25, 2015 --> ... eine Lizenz für das Patent über eine neue Hepatitis-B-Behandlung, ... ENS-Lyon innehaben, an Enyo Pharma vergeben haben. ... Leben gerufenen und von Edelris gemeinsam mit seinen Partnern ... Behandlungsziel für HBV identifiziert, und es wurden neue Inhaltsstoffe ...
Breaking Medicine Technology: